Basilea Pharmaceutica AG

SWX:BSLN Stock Report

Market Cap: CHF 501.2m

Basilea Pharmaceutica Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of BSLN?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders6,5760.0543%
Institutions4,113,96533.9%
General Public8,000,58966%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 33.14% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
10.8%
Black Creek Investment Management Inc.
1,307,362CHF 54.1m0%0.91%
5.36%
UBS Asset Management AG
649,298CHF 26.8m-22.2%no data
3.77%
The Vanguard Group, Inc.
457,336CHF 18.9m-0.03%no data
2.74%
Acatis Anlageberatung fur Investmentfonds GmbH
332,600CHF 13.8m0%1.06%
1.82%
BlackRock, Inc.
220,880CHF 9.1m1.33%no data
1.43%
JPMorgan Chase & Co, Private Banking and Investment Banking Investments
173,161CHF 7.2m0%no data
1.34%
ZKB Asset Management
162,717CHF 6.7m-15.9%0.02%
0.96%
Norges Bank Investment Management
116,576CHF 4.8m0%no data
0.95%
Dimensional Fund Advisors LP
114,927CHF 4.8m-8.45%no data
0.56%
Saint Olive Gestion
67,500CHF 2.8m0%0.34%
0.51%
Zürcher Kantonalbank, Investment Arm
62,412CHF 2.6m-14.7%0.02%
0.41%
JP Morgan Asset Management
49,459CHF 2.0m0%no data
0.32%
Pictet Asset Management SA
38,858CHF 1.6m0%no data
0.27%
Deka Investment GmbH
33,056CHF 1.4m0%no data
0.27%
CI Global Asset Management
32,935CHF 1.4m0%no data
0.24%
Medical Strategy GmbH, Asset Management Arm
29,464CHF 1.2m0%0.08%
0.22%
BCV Asset Management
26,605CHF 1.1m120%0.03%
0.21%
Principal Vermoegensverwaltung AG
26,000CHF 1.1m0%1.03%
0.19%
Charles Schwab Investment Management, Inc.
23,069CHF 953.9k0%no data
0.14%
Deutsche Asset & Wealth Management
17,504CHF 723.8k0%no data
0.14%
PMG Investment Solutions AG
16,940CHF 700.5k0%0.24%
0.13%
Rieter Fischer Partners
16,125CHF 666.8k0%0.42%
0.12%
Amundi Asset Management SAS
14,877CHF 615.2k0%no data
0.12%
Assenagon Asset Management S.A.
14,349CHF 593.3k0%no data
0.11%
State Street Global Advisors, Inc.
12,964CHF 536.0k-5.55%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 11:13
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Basilea Pharmaceutica AG is covered by 26 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Leonildo DelgadoBaader Helvea Equity Research
Volker BosseBaader Helvea Equity Research
Markus MayerBaader Helvea Equity Research